Disclosures for "Risdiplam: Therapeutic Effects and Tolerability in a Small Cohort of 6 Adult Type 2 and Type 3 SMA Patients"
-
Dr. Severa has received research support from Généthon, UPEC.
-
Mr. Alimi has nothing to disclose.
-
Dr. Malfatti has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Spark therapeutics. Dr. Malfatti has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sarepta. The institution of Dr. Malfatti has received research support from AFM. The institution of Dr. Malfatti has received research support from Spark Therapeutics.